Abstract:Background: Tigecycline, a glycylcycline antibiotic, is increasingly used clinically for the treatment of severe infections caused by multidrug-resistant bacteria, but it is also associated with hepatotoxicity. However, the incidence and risk factors of tigecycline-associated drug-induced liver injury (DILI) are unclear. We conducted this study to investigate the incidence, characteristics and risk factors of tigecycline-associated DILI in the real-world clinic setting. Patients and Methods: A retrospective analysis was conducted in inpatients who received tigecycline treatment from January 2018 to January 2020. Based on the biochemical criteria of DILI and the causality assessment by Roussel Uclaf Causality Assessment Method (RUCAM) using cases with a probable or highly probable causality grading, two clinical pharmacists and one clinician worked together to screen patients for tigecycline-associated DILI. Then patients with DILI were randomly matched by gender in a ratio of 1:2 to the remaining patients in the tigecycline cohort without biochemical abnormalities to identify risk factors. Results: A total of 973 patients from 1,250 initial participants were included. The incidence of tigecycline-associated DILI was 5.7% (55/973). Among 55 DILI patients, 10 cases presented with the hepatocellular pattern, 4 cases belonged to the mixed pattern, and 41 presented with the cholestatic pattern. Most cases reached the severity of grade 1 and 2. The rate of recovery in hepatocellular pattern, mixed pattern, and cholestatic pattern was 70.0, 50.0, and 41.5%, respectively. The proportion of the DILI cases treated with high dose (100 mg) and prolonged duration (>14 days) was significantly higher than standard dose and routine duration (100.0% vs. 18.1%, p < 0.05). Logistic regression analysis showed that high maintenance dose (OR = 1.028, p = 0.002), prolonged duration (OR = 1.208, p = 0.000), and number of hepatotoxic drugs (OR = 2.232, p = 0.000) were independent factors of tigecycline-associated DILI. Conclusion: Tigecycline was associated with liver injury, with a slightly higher incidence (5.7%) than the frequency of “frequent” (5%) defined by the Medical Dictionary for Regulatory Activities. Patients with a high maintenance dose and prolonged tigecycline regimen, as well as concomitant use of multiple hepatotoxic drugs should be paid more attention.

Drug-Induced Liver Injury Due to Doxycycline: A Case Report and Review of Literature

Analysis and Prevention of Liver Injury Caused by Azithromycin:a Retrospective Study of 27 Cases

A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data

A case report of drug-induced liver injury after tigecycline administration: histopathological evidence and a probable causality grading as assessed by the updated RUCAM diagnostic scale

Analysis of 572 Cases of Drug-induced Liver Injury Induced by Anti-infective Agents

A unusual presentation of liver failure caused by Ibuprofen-sustained release capsules: A case report

Doxycycline-associated acute pancreatitis: a rare adverse effect of a commonly prescribed antibiotic

Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases

Hepatotoxicity of Antibiotics and Antifungals and Their Safe Use in Hepatic Impairment

Real-World Data of Tigecycline-Associated Drug-Induced Liver Injury among Patients in China: A 3-Year Retrospective Study As Assessed by the Updated RUCAM

Antibiotics enhancing drug-induced liver injury assessed for causality using Roussel Uclaf Causality Assessment Method: Emerging role of gut microbiota dysbiosis

[The Clinical Features and Prognosis of Drug-Induced Liver Disease].

Idiosyncratic drug-induced liver injury: an overview

Drug-induced acute interstitial nephritis:case report and literature review

Delayed Presentation of Drug-Induced Hepatic Injury

Fosfomycin-induced liver injury: A case report and literature review

Clinial Analysis about Drug-Induced Liver Disease(51 Cases)

Brief Communication: Severe Hepatotoxicity of Telithromycin: Three Case Reports and Literature Review

Drug-induced liver injury in 2007

Severe Drug-Induced Liver Injury From Over-the-Counter Medication

S4190 A Case Report of Drug-Induced Liver Injury From Norethindrone Acetate